Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esflurbiprofen transdermal - Taisho Pharmaceutical

Next Previous
Drug Profile

Esflurbiprofen transdermal - Taisho Pharmaceutical

Alternative Names: Esflurbiprofen plaster; LOQOA Tape; S-Flurbiprofen; SFPP; TT-063

Latest Information Update: 22 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tokuhon Corporation
  • Developer Taisho Pharmaceutical; Tokuhon Corporation
  • Class Analgesics; Antirheumatics; Biphenyl compounds; Fluorobenzenes; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammation; Pain
  • Discontinued Muscle pain; Periarthritis

Most Recent Events

  • 22 Feb 2023 No development reported - Phase-III for Pain in Indonesia (Transdermal)
  • 22 Feb 2021 Esflurbiprofen transdermal is still in phase III trials for Pain in Indonesia (Transdermal) (NCT03434197)
  • 11 Jan 2021 Taisho Pharmaceutical completes a phase III trial in Pain (in patients with knee osteoarthritis) in Indonesia (Transdermal) (NCT03434197)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top